Department of Pharmacology, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir, Turkey.
Department of Pharmacology, Johannes Gutenberg University, Langenbeckstr. 1, 55131, Mainz, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2022 Apr;395(4):381-386. doi: 10.1007/s00210-022-02221-7. Epub 2022 Feb 17.
Numerous studies in airways, ileum, and urinary bladder have demonstrated that relaxation by β-adrenoceptor agonists has lower potency and/or efficacy when contraction was elicited by muscarinic receptor agonists as compared to other G-protein-coupled receptors, KCl, or basal tone, but the molecular mechanisms behind this relative resistance remain unclear. A paper by Huang et al. in this issue demonstrates that NAV2729, an inhibitor of ADP ribosylation factor 6, inhibits contraction of isolated blood vessels elicited by muscarinic receptor agonists, but not by α-adrenoceptor agonists or KCl. Against this background, we discuss the role of ADP ribosylation factor 6 in cellular responses to G-protein-coupled receptor stimulation. While ADP ribosylation factor 6 apparently is the only promising molecular explanation for the relative resistance of smooth muscle contraction elicited by muscarinic agonists, the existing data are insufficient for a robust conclusion.
许多关于气道、回肠和膀胱的研究表明,与其他 G 蛋白偶联受体、KCl 或基础张力相比,当用毒蕈碱受体激动剂引发收缩时,β-肾上腺素受体激动剂的松弛作用的效力和/或功效较低,但这种相对抗性的分子机制仍不清楚。本期Huang 等人的一篇论文表明,ADP 核糖基化因子 6 抑制剂 NAV2729 可抑制由毒蕈碱受体激动剂引发的分离血管的收缩,但不能抑制由α-肾上腺素受体激动剂或 KCl 引发的收缩。在此背景下,我们讨论了 ADP 核糖基化因子 6 在细胞对 G 蛋白偶联受体刺激反应中的作用。虽然 ADP 核糖基化因子 6 显然是毒蕈碱激动剂引发的平滑肌收缩相对抗性的唯一有希望的分子解释,但现有数据不足以得出可靠的结论。